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Abstract
Background: The purpose of this study was to use insurance claims and tumor registry data to
examine determinants of breast conserving surgery (BCS) in women with early stage breast cancer.
Methods: Breast cancer cases registered in the Hawaii Tumor Registry (HTR) from 1995 to 1998
were linked with insurance claims from a local health plan. We identified 722 breast cancer cases
with stage I and II disease. Surgical treatment patterns and comorbidities were identified using
diagnostic and procedural codes in the claims data. The HTR database provided information on
demographics and disease characteristics. We used logistic regression to assess determinants of
BCS vs. mastectomy.
Results: The linked data set represented 32.8% of all early stage breast cancer cases recorded in
the HTR during the study period. Due to the nature of the health plan, 79% of the cases were
younger than 65 years. Women with early stage breast cancer living on Oahu were 70% more likely
to receive BCS than women living on the outer islands. In the univariate analysis, older age at
diagnosis, lower tumor stage, smaller tumor size, and well-differentiated tumor grade were related
to receiving BCS. Ethnicity, comorbidity count, menopausal and marital status were not associated
with treatment type.
Conclusions: In addition to developing solutions that facilitate access to radiation facilities for
breast cancer patients residing in remote locations, future qualitative research may help to
elucidate how women and oncologists choose between BCS and mastectomy.
Background
In 1990 the National Institutes of Health Consensus De-
velopment Conference [1] concluded that breast conserv-
ing surgery (BCS) followed by radiation is an appropriate
method of primary treatment for the majority of women
with early stage breast cancer (AJCC stages [2] I, IIA, and
IIB). Numerous clinical studies have shown that survival
after BCS followed by radiation therapy is equivalent to
survival following mastectomy for women in these stages
[3–5]. Some absolute indicators for mastectomy remain
[6,7], in particular widespread malignant-type microcalci-
fications, previous radiotherapy, and a relation of tumor
size to breast size that would not allow a cosmetically sat-
isfactory result. Although there has been an increase in the
use of BCS since the early 1990s, an apparent under-utili-
zation of BCS among women for whom such treatment
was not contraindicated has been documented [8]. Geo-
graphic location, type of hospital and health plan, and
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personal preferences have been investigated as possible
factors to explain the continued use of mastectomy [9–
12]. Comorbidity [13] has been found to be an important
predictor among older women.
The Surveillance, Epidemiology and End Results (SEER)
cancer registries do not collect sufficient detail to examine
some of these issues and medical records reviews are time
consuming. Insurance claims data are a cost-effective al-
ternative; they have already been collected and put into an
electronic format by the insurance carriers. They cover
large segments of the population, allow follow-up, use
standardized codes [14,15], and do not rely on subject re-
call. In cancer research, insurance claims data have been
used to estimate the effectiveness of cervical cancer screen-
ing [16], to assess the role of screening practices in the in-
cidence of prostate cancer [17], and to estimate
mammography participation [18]. Medicare enrollees in
Seattle and San Francisco who received care from a Health
Maintenance Organization (HMO) were found to receive
more BCS than women in Fee-For-Service (FFS) plans
[19]. Whereas a Medicare/SEER registry linked data set has
been used extensively to examine treatment and screening
issues in individuals 65 years and older [20], linking of in-
surance claims data from private health plans in younger
populations has been more difficult because of the large
number of health plans in most geographic areas. Howev-
er, Hawaii provides unique opportunities for insurance
claims research because the majority of medical care is re-
ceived within the state and more than 90% of the popula-
tion [21] are covered by a limited number of health plans.
As a pilot project, we were able to link data from the Ha-
waii Tumor Registry and from a health plan in Hawaii.
The objectives of this analysis were to describe breast can-
cer treatment and comorbid conditions using the insur-
ance claims data and to examine possible determinants of
BCS vs. mastectomy for breast cancer patients with stage I
and II disease.
Methods
The study protocol was reviewed and approved by the
University of Hawaii's Committee on Human Studies and
by the Hawaii Tumor Commission that oversees the Ha-
waii Tumor Registry (HTR). Before linking of databases
was initiated, a memorandum of agreement between all
parties involved in this research project was signed. The re-
sulting agreement safeguarded patients' privacy at the
highest possible level. All names and identifying informa-
tion were deleted from the datasets and replaced with ar-
bitrary numbers to be used for the data analyses.
Data Sources
The HTR has maintained a database of all cases of cancer
diagnosed in the State of Hawaii since 1960 and became
part of the SEER program in 1973. The HTR record con-
tains demographic characteristics such as age, ethnicity,
marital status, island of residence, as well as information
on tumor size, extent of disease, lymph node involve-
ment, and tumor grade. From medical records in hospitals
and physicians' offices, information is collected on the in-
itial course (six months in the Hawaii Tumor Registry) of
cancer-directed treatment following diagnosis. Quality
control reviews have shown that case-ascertainment
through HTR has been virtually complete [22]. Over 99%
of cancer cases reported to the registry are histologically
confirmed. The HTR also maintains a link with Hawaii
Department of Health, which allows for death informa-
tion to be captured in the HTR database.
Linking
The insurance claims for this study were obtained from a
local insurer who was a party to the memorandum of
agreement. The linked data set contained cancer cases di-
agnosed from 1995 through 1998. During the linking
process, a list of health plan members who had at least
two cancer diagnostic codes in their claims history were
matched against the HTR using a probabilistic method.
For each matched record, the health plan furnished all
claims data for that period. They also indicated whether
the individual was enrolled in a Fee-For-Service (FFS) or a
capitated (HMO) plan, a choice provided by the insurer.
However, the majority of linked cancer cases belonged to
the FFS plan and the HMO plan provided by this insurer
differs considerably from a typical HMO. Individuals aged
65 years and older were included only if they were still
working and had primary coverage through the health
plan or if they were covered under Medicare but also had
secondary coverage through the health plan. The dataset
furnished by the health insurer contained all claims proc-
essed for cancer patients in this study. The data elements
included: date of service, International Classification of
Disease, version 9 (ICD-9) diagnosis codes [14], Current
Procedural Terminology (CPT) codes [15], and the pro-
vider specialty code. The dataset contained claims for serv-
ices from physicians, laboratories, freestanding facilities,
as well as outpatient services provided by hospital facili-
ties.
Data set
Breast cancer cases accounted for 16.6% of all cancer cases
recorded in the HTR during the period from 1995 to 1998.
In the linked dataset, 27.7% of the cases were breast can-
cer cases. Using the ICD-9-CM code range [14] for breast
cancer (174.0 to 174.9), we identified 1,377 female breast
cancer cases. We then excluded 265 cases diagnosed after
June 30, 1998 because we would not have a complete his-
tory of claims data covering at least six months of treat-
ment. We also identified 30 women who had been
recorded twice in the linked dataset because breast cancer
was diagnosed in both breasts, as identified by the lateral-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/3
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ity codes. For 24 women, the diagnosis date was identical,
in which case we considered the two diagnoses as one
case. For the six cases with different diagnoses dates, we re-
tained both records because there was a separate complet-
ed course of treatment for the cancer in each breast. We
eliminated one case that was in the linked dataset and had
inpatient data but no outpatient data, resulting in a data-
set containing 1,088 breast cancer cases.
Staging
We used the HTR information in the Extent of Disease
(EOD-10) field [23] to determine the American Joint
Committee on Cancer (AJCC) TNM stage [2], where T rep-
resents the primary tumor size, N refers to lymph node in-
volvement, and M refers to presence of metastases. In
cases where the tumor size was unknown, we assigned a
stage only if the size was not a determinant in the TNM
grouping. If the extension was unknown, we equated it to
extension 10 (confinement to breast tissue and fat). For
the small number of cases (N = 8) for whom lymph node
involvement code was unknown, we considered this the
same as no lymph node involvement because the tumor
size was so small for these cases that a lymph node dissec-
tion was not considered necessary at the time of this
study. The results of the TNM staging agreed well with the
SEER summary stage codes.
Cancer treatment
We used the CPT codes [15] in the claims dataset to iden-
tify the type of surgery performed. For mastectomies, we
included codes for simple and subcutaneous mastecto-
mies (19180 and 19182), radical mastectomies (19200
and 19220) and modified radical mastectomy (19240).
BCS was identified by the CPT codes for partial mastecto-
mies (19160, 19162). We also included codes for excision
of breast cysts or lesions (19120 and 19125) as these
codes meet the definition of a lumpectomy, although we
recognize that some surgeons may have billed these codes
for excisional biopsies as a diagnostic procedure. If BCS
was initially performed, but followed by a subsequent
mastectomy, the subject was classified in the mastectomy
group. This situation would have occurred when the BCS
code was actually used for a diagnostic biopsy and the
subsequent surgical treatment was a mastectomy or in sit-
uations where a lumpectomy was first selected, but a mas-
tectomy became necessary because pathological
examination revealed cancerous cells in the margins of the
excised tissue. CPT codes 77261 to 77799 were selected to
determine whether radiation therapy was received. Several
CPT codes and also a number of other codes used by the
health plan for billing were considered evidence of chem-
otherapy treatment.
Comorbidities
Information on the existence of comorbidities was extract-
ed from the claims data using the occurrence of ICD-9
codes associated with comorbid conditions included in
the Charlson Index [24]. We also analyzed data for condi-
tions that were not included in that index, but occurred at
a high enough frequency to warrant examination as possi-
ble comorbidities, in particular hypertension and lipid
disorders. We included the following twelve comorbid
conditions into our index: diabetes with complications,
diabetes w/o complications, hypertension, heart disease,
cerebrovascular disease, chronic pulmonary disease, pe-
ripheral vascular disease, kidney disease, liver disease,
rheumatological diseases, hypothyroidism, and lipid me-
tabolism disorders. Comorbidities were based on physi-
cians' claims with the respective ICD-9 code [14] during
the 12-months period preceding the month in which the
cancer was diagnosed. The month of diagnosis was ex-
cluded to avoid identifying as comorbidities any compli-
cations or conditions directly resulting from cancer
treatment. Laboratory, radiology, and other diagnostic
services were excluded from the comorbidity identifica-
tion process because tests may have been done to rule out
the condition. Each subject was assigned a comorbidity
score of 0 (no condition), 1 (one condition), or 2 (two or
more conditions).
Other variables
In addition to stage at diagnosis and size of tumor, we ex-
amined several other variables that were possible determi-
nants in the utilization of BCS vs. mastectomy in early
stage breast cancer, including age at diagnosis, ethnicity,
island of residence, and marital status. For ethnicity, we
used the five major groups in Hawaii (Japanese, Cauca-
sian, Hawaiian, Filipino, and Chinese). All other ethnici-
ties were grouped into an "Other" category. The specific
island of residence was coded in the HTR, but since close
to 80% of the population resides on Oahu [25], we classi-
fied residence as either Oahu or non-Oahu. For marital
status, we grouped all women who were identified as sin-
gle, separate, divorced or widowed in the unmarried cate-
gory. Women under age 50 were considered pre-
menopausal and women 50 years and older were classi-
fied as postmenopausal. Tumor grade information from
the HTR record was grouped into grade I (well-differenti-
ated cells) vs. all other grades (II, III, IV and unknown).
Statistical analysis
All analyses were performed with SAS version 8.00 for
Windows (SAS Institute, Cary, NC). Simple Kappa statis-
tics (κ ) was calculated to validate the treatment informa-
tion from the insurance claims and the HTR [26,27]. BCS
was used as reference group throughout the analysis. It
was defined as the dependent (outcome) variable and
coded as a dichotomous variable, with 1 indicating BCSBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/3
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received and 0 indicating mastectomy received. Age was
entered in units of ten years and tumor size was grouped
into units of ten millimeters (one centimeter). For analy-
ses of ethnicity as a predictor of treatment selection, Cau-
casian was used as the control group and indicator
variables for all other ethnic groups were created. Logistic
regression [28] was used to explore the influence of each
variable on the use of BCS vs. mastectomy. First, we con-
sidered each independent variable by itself in a model and
then we entered all variables simultaneously in a logistic
regression model. Odds Ratios (OR) [29] with corre-
sponding 95% Confidence Intervals (CI) were calculated
to measure the degree of influence of variables on the uti-
lization of BCS vs. mastectomy.
Results
Based on the TNM stages, we identified 722 women who
had stage I, IIA, or IIB breast cancer (66.4% of the 1,088
breast cancer cases in the linked data set). These 722 cases
represented 32.8% (722 of 2,203 cases) of all early stage
breast cancer cases recorded in the HTR during the study
period. Approximately two-thirds of the women in the
study population (Table 1) were diagnosed in stage I of
the disease and only 24% and 12% in stage IIA and IIB, re-
spectively. Approximately 30% of the study subjects were
aged less than 50 years, close to half were 50 to 64 years
old, and 21% were 65 years and older. Three out of four
women resided on the island of Oahu. Overall, 52.8% of
the women had received BCS. Of the cases diagnosed at
stage I, 57% of the women had received BCS and 47% a
mastectomy. This decreased to 50% for stage IIA and to
34% for stage IIB. Among women, 65 years and older,
56% had BCS, compared to 50% of those under 50 years
of age and 53% of the 50–64 year old women. While 56%
of women on Oahu underwent BCS, only 43% of the
women residing on the outer islands received BCS. We ob-
served no statistically significant differences between the
BCS and mastectomy group in terms of ethnicity, comor-
bidity count, menopausal status, marital status, and insur-
ance plan. We found very high agreement between HTR
data and claims data in identifying BCS [κ  = 0.91 (95% CI
0.88, 0.94)], only 32 women were misclassified. For the
majority of women who received BCS (92.1%), the
lumpectomy was followed by radiation therapy. Addi-
tional chemotherapy was given to 34.1% and 42.5% of
the women who had a lumpectomy or a mastectomy, re-
spectively.
In the univariate models (Table 1), we found that tumor
size and grade, island of residence, age, and stage at diag-
nosis were predictors of breast cancer treatment. Women
residing on Oahu were considerably more likely to have
BCS than women living on all other islands in the state.
For each one-centimeter increase in tumor size, there was
a 3% lesser chance of undergoing BCS. Since size of tumor
correlates to breast cancer stage, this also decreased the
likelihood for women in stage IIA and IIB to receive BCS.
Women with well-differentiated tumor grades were 50%
more likely to undergo BCS as compared to women with
all other grades. We found that for each ten-year incre-
ment in age, the chances of having BCS increased by 1%.
We also observed that average tumor size was inversely re-
lated to age. Mean tumor sizes (in cm) with standard de-
viations were 1.82 ± 1.1, 1.59 ± 1.2, 1.39 ± 0.94 for
women younger than 50 years, 50 to 64 years, and 65
years and older, respectively. Therefore, the smaller tumor
sizes may account for the greater likelihood of BCS among
older women.
In a combined model with all independent variables in a
logistic regression, island of residence remained the only
significant predictor of BCS in this population. Women
living on Oahu were 67% more likely to have BCS than
women on the outer islands. Although all other variables
lost their statistical significance, associations for age, TNM
stage, tumor size, and tumor grade remained similar in
magnitude as in the univariate models. Although none of
the ethnicity variables was significant, it appeared that Fil-
ipino women were less likely to receive BCS than women
from all other groups. Residence on outer islands did not
explain this observation. Women with a TNM stage of IIB
were still 40% less likely to receive BCS than women diag-
nosed at stage I, but the relation lost its statistical signifi-
cance due to the small number of cases. Menopausal or
marital status, type of health plan, or the number of co-
morbidities were not related to the type of surgery.
Discussion
The place of residence at the time of diagnosis was the
most important predictor for receiving BCS in this dataset
of health plan members. Women with early stage breast
cancer living on Oahu were 70% more likely to have BCS
than women living on outer islands. Age at diagnosis and
tumor size were also related to breast cancer treatment al-
though they were not statistically significant in the com-
bined model. Contrary to our expectation and a previous
publication [13], the number of comorbid conditions did
not effect treatment in this analysis. The importance of ge-
ographic location can be explained by the availability of
radiation facilities on the different Hawaiian Islands.
Whereas on Oahu treatment facilities can be reached
within one hour, distances on the outer islands are much
farther. Only the Island of Hawaii and Maui have a radia-
tion facility, but they are hard to reach from many parts of
the islands. Women residing on Kauai, Molokai, and La-
nai have to fly to Honolulu daily to receive the course of
treatment or they have to remain there temporarily. Be-
cause this may be not be economically feasible for some
women, as well as physically and psychologically chal-
lenging, it is possible that many women choose to under-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/3
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Table 1: Determinants of Breast Conserving Surgery Among 722 Cases of Early Stage Breast Cancer
Variable No. of patients Odds ratio (95% CI)
BCS Mastectomy Univariate analysis Combined analysis
All 381 341
Ethnicity Caucasian 71 66 1 1
Japanese 170 147 1.08 (0.72–1.61) 0.85 (0.55–1.31)
Hawaiian 48 40 1.12 (0.65–1.91) 1.24 (0.71–2.17)
Filipino 35 47 0.69 (0.39–1.20) 0.65 (0.37–1.15)
Chinese 32 25 1.19 (0.64–2.22) 0.97 (0.50–1.86)
Other 24 16 1.45 (0.71–2.96) 1.33 (0.64–2.77)
Residence Oahu 299 232 1.71 (1.23–2.39) 1.67 (1.17–2.38)
Other 82 109 1 1
Age at diagnosis <50 yrs 110 109 Continuous (per 10 years)
50–64 yrs 186 166 1.01 (1.001–1.028) 1.01 (0.99–1.04)
65+ yrs 85 66
Menopausal status Pre Post 110 271 109 232 1 1.16 (0.84–1.59) 1 0.75 (0.46–1.23)
Marital status Married 262 244 0.88 (0.64–1.21) 0.94 (0.68–1.32)
Unmarried 119 97 1 1
Health plan FFS 330 300 0.89 (0.57–1.37) 0.87 (0.55–1.38)
HMO 51 41 1 1
TNM stage I 266 200 1 1
IIA 86 85 0.76 (0.54–1.08) 0.99 (0.66–1.51)
IIB 29 56 0.39 (0.24–0.63) 0.61 (0.32–1.19)
Tumor size <1 cm 113 83 Continuous (per 1 cm)
1–1.9 cm 177 139 0.97 (0.96–0.99) 0.98 (0.96–1.00)
2 + cm 91 119
Tumor grade Well diff. 77 49 1.51 (1.02–2.24) 1.25 (0.83–1.89)
Other 304 292 1 1
Comorbid conditions 0 230 201 Continuous (per score)
1 109 102 0.97 (0.78–1.19) 0.91 (0.72–1.14)
2+ 42 38BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/3
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go a mastectomy instead. Alternatively, patients and
physicians in rural areas may favor mastectomy because of
differences in education or cultural attitudes toward med-
ical advances. We do not have information to explain why
a small proportion of women who underwent BCS (6.9%)
did not receive radiation. However, compared to other re-
ports [13,30,31], the proportion of women who received
radiation is very high. An interview study with cancer pa-
tients [32] showed that some patients decide against their
physicians' recommendation for radiation because they
fear the treatment or hold certain beliefs about cancer. For
other patients, radiation may have been contraindicated
due to comorbid conditions.
In 1994, a national BCS rate of 42.6% was reported [33]
with a rate of 46.7% for the Pacific region (Hawaii, Cali-
fornia, Alaska, Washington, and Oregon). Our results for
1995 to 1998 indicate a slightly higher rate for Hawaii
(52.8%). Geographic differences in BCS use have repeat-
edly been described in the literature. In western Washing-
ton [34], women residing outside the Seattle area were less
likely to have BCS than women residing inside the county,
in particular if radiation therapy facilities were not availa-
ble in their county. Comparing rates across the country
showed that BCS was much more common in the North-
east than in the South [33]. Low BCS rates were also found
in rural areas, such as North and South Carolina [10],
Minnesota [35], and the Southwest [36]. An analysis of
1991–1992 SEER data [37] demonstrated a strong associ-
ation between BCS and distance to the next radiotherapy
facility. The likelihood of undergoing BCS was 50% lower
among women living more than 15 miles from the next
radiotherapy facility.
In contrast to our results, a number of studies have shown
that the likelihood of BCS decreases with increasing age
[11,30,33], possibly due to less concern about cosmetic
results. Because of the relatively small proportion (21%)
of women 65 years and older and the fact that the women
65 years and older in our study had a health plan other
than Medicare, they were not directly comparable to the
populations in the published literature. Therefore, our
ability to observe an effect among older women was lim-
ited. In particular, we were not able to examine the treat-
ment of women 80 years and older who have been
described as receiving more BCS than women age 65 to 79
years [13]. Our findings of lower BCS in smaller and well
differentiated tumors agree with previous studies [33], but
the absence of an effect of comorbid conditions disagrees
with a study in older women [13] that showed a higher
rate of BCS in women with comorbidities. Type of health
plan did not predict type of treatment in our study proba-
bly because the majority of women in this data set had a
FFS plan. In previous analyses with a larger variety of
health plans, HMO members were considerably more
likely to receive BCS in San Francisco and in Seattle [19].
Medicare and Medicaid patients received more BCS in a
North Carolina hospital [7]. However, a study using ad-
ministrative data [38] described lower BCS use among
Medicaid patients and treatment was similar by health
plan [39] in Northern California.
Our study had several limitations, including the possibil-
ity of incomplete claims histories if patients changed
health plans during the course of treatment, but the high
agreement with HTR information indicates that the valid-
ity of insurance claims information was high. Continuing
efforts by the health plan through feedback loops has im-
proved diagnostic coding [40] in Hawaii, but as docu-
mented for Medicare claims, problems remain [41]. As
discussed above, our study sample of breast cancer pa-
tients does not represent the population of the state, ex-
cluding in particular Medicare and Medicaid recipients,
members of a typical HMO, and the relatively small
number of uninsured patients. The exclusion of Medicare
claims lead to a younger population, whereas the lack of
Medicaid claims biased the cases toward a higher socioe-
conomic status. On the other hand, the study population
represented the population quite well in terms of ethnici-
ty (Hawaii Department of Business 1998 1705 /id). Be-
cause our data set included 42.4% of all breast cancer
cases under 65 years diagnosed during the study period,
the results represents this population much better than
the population of older women. Also, we were unable to
measure some factors that have been found to be impor-
tant in other reports, in particular, influence of physician
age [11], physician specialty [42], type of hospital (teach-
ing hospitals and hospitals with radiation facilities, pri-
vate, county and public) [36,38,39,43], socio-economic
status and education [42], tumor-breast ratio and the ex-
pected cosmetic results [7,9], physician/patient interac-
tions before surgery [42], and psychological factors, such
as fear of radiation or cancer [9]. The strengths of using of
insurance claims data for this analysis were twofold. First,
we had more detailed treatment information available
than collected by the tumor registry. Second, the diagnos-
tic codes in the claims data allowed us to estimate the
number of comorbid conditions before the cancer diagno-
sis.
The results of this pilot study combining tumor registry
and insurance claims data raises an important issue for
cancer practice in the State of Hawaii and elsewhere.
Health care providers and insurance plans need to work
with other agencies to develop viable solutions to facili-
tate access to radiation facilities for women residing in re-
mote locations, such as islands with no radiation facility.
Attitudes of patients and physicians living in rural areas
may be important in the choice of treatment, but could
not be investigated in this project. Future research that in-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/3
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cludes interviews with patients and physicians may inves-
tigate attitudes toward certain types of treatment and
identify additional barriers to BCS, such as psychological
problems. In order to understand how treatment deci-
sions were made in practice, qualitative information from
physicians and breast cancer patients should be collected
and examined in detail. Further validation of treatment
and comorbidity from insurance claims data would
strengthen this type of research in the future. The inclu-
sion of a larger proportion of breast cancer cases is needed
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